Mental Health
News Category

NanoViricides Advances NV-387 into Phase 2 Trials for Ebola and Mpox, Eyes Measles with FDA Designations
NanoViricides has initiated two Phase 2 clinical trials for its broad-spectrum antiviral NV-387 in Ebola and mpox, while leveraging FDA designations t...

iPSC Neural Models Offer Disease-Relevant Alternatives for Early Drug Discovery
Creative Biolabs is promoting complementary iPSC differentiation, neural model, and microfluidic culture solutions to help researchers select laborato...

Quantum BioPharma's $12.22 Million in Cash and Digital Assets Fuels Lucid-MS Phase 2 Trial
Quantum BioPharma's Q3 2026 results show $12.22 million in cash and digital assets, a 91% equity increase, and a key Phase 2 trial agreement for Lucid...

Understanding Clinical Trial Phases: A Path to Better IBD Treatments
Clinical trials are essential for developing new treatments for inflammatory bowel disease, but participation, especially from underrepresented groups...

Novogenia to Supply DNA Analytics and Personalized Supplements for GLP-1 Clinical Study in Abu Dhabi
Novogenia AG will conduct DNA analyses and manufacture personalized dietary supplements for a planned 500-participant clinical study in Abu Dhabi, aim...

BioVersys to Unveil New Alpibectir Data at The Union World Conference on Lung Health
BioVersys and GSK will present Phase 2 data on alpibectir-ethionamide for tuberculosis at The Union World Conference, potentially advancing a much-nee...

NanoViricides Advances NV-387 Toward Phase II Trials for Measles
NanoViricides is advancing its broad-spectrum antiviral NV-387 toward Phase II clinical trials for measles, addressing a rising unmet medical need wit...

American Heart Association Honors MedRhythms and Vascudyne at Scientific Sessions 2026
The American Heart Association's Health Tech Competition awarded MedRhythms and Vascudyne top honors, highlighting technologies that could transform s...

Tonix Pharmaceuticals Q3 2026 Revenue Jumps to $17.2 Million on TONMYA Strength
Tonix Pharmaceuticals reported third-quarter 2026 net product revenue of $17.2 million, driven by 37% sequential growth in TONMYA sales, and extended ...

Lifordi's LFD-200 Shows Early Promise in Delivering Glucocorticoids Without Systemic Toxicity
Lifordi Immunotherapeutics' Phase 1 data for LFD-200, a subcutaneous antibody-drug conjugate, demonstrates tolerability and anti-inflammatory effects ...

Left Bundle Branch Pacing Outperforms Standard Right Ventricular Pacing in Heart Block, Trial Finds
A major international trial shows that left bundle branch pacing reduces death, heart failure hospitalization, and pacing-induced cardiomyopathy compa...

Intensive Blood Pressure Targets Cut Second-Stroke Risk in Survivors, OPTIMAL-Stroke Trial Finds
A Brazilian trial of more than 4,000 stroke and TIA survivors found that pushing systolic blood pressure below 120 mm Hg reduced major cardiovascular ...

Low-Cost Diuretic Spironolactone Lowers Blood Pressure After Stroke
Adding spironolactone to post-stroke care significantly lowers blood pressure and doubles the rate of reaching blood pressure goals, offering a cheap ...

ZEUS Trial Neutral Results Reinforce Inflammation as Key Cardiovascular Target
Despite lowering inflammatory markers, ziltivekimab failed to reduce cardiovascular events in high-risk patients, underscoring the need for earlier in...

EGFR Signaling Emerges as Key Target for Airway Mucus Hypersecretion
A new review identifies EGFR signaling as a central driver of airway mucus hypersecretion and evaluates potential therapies, offering hope for disease...

Pediatric Stroke Burden Shifts to Adolescents and Low-Income Regions, Study Finds
Global pediatric stroke deaths and disability have fallen since 1990, but rising adolescent incidence and persistent hemorrhagic stroke mortality in l...

Quantum BioPharma Targets Unmet Neurological Needs with Science-First Strategy
Quantum BioPharma is advancing a diversified strategy that combines drug development, consumer wellness, and royalty partnerships to address the vast ...

Annovis Bio's Proposed Public Offering to Fund Buntanetap Trials for Alzheimer's and Parkinson's
Annovis Bio's proposed public offering aims to raise capital to advance its lead drug candidate buntanetap through clinical development for Alzheimer'...

Tonix Pharmaceuticals to Present at Guggenheim Healthcare Innovation Conference, Spotlighting Commercial-Stage CNS and Immunology Strategy
Tonix Pharmaceuticals' upcoming presentation at the Guggenheim Healthcare Innovation Conference highlights its commercial-stage portfolio, including t...

Quantum BioPharma's Dual Strategy Targets Neurological Disorders and Consumer Wellness
Quantum BioPharma is advancing a diversified strategy that pairs its lead drug candidate Lucid-MS for demyelination with consumer wellness products an...

Quantum BioPharma's Unbuzzd Gains Credibility with Men's Fitness Review of Placebo-Controlled Trial
Quantum BioPharma's unbuzzd supplement, designed to support alcohol metabolism, has drawn praise from Men's Fitness after a placebo-controlled trial s...

Quantum BioPharma's Unbuzzd Draws Men's Fitness Attention as Trial Shows Early Promise
Quantum BioPharma's unbuzzd supplement, designed to support alcohol metabolism, has been highlighted by Men's Fitness for promising early clinical tri...

Okogen Doses First Patient in EMERALD Trial for Acute Infectious Conjunctivitis
Okogen has dosed the first patient in its Phase 1/2 EMERALD Trial of Treyegen, a potential single therapy for acute infectious conjunctivitis, marking...

AI-Guided Heart Scans in Mobile Units Show Promise for Rural Care
Preliminary research shows that non-experts using AI guidance can perform quality heart scans in mobile units, potentially improving access to cardiac...

Heat Waves Linked to Surge in Cardiac Arrest ICU Admissions, Especially Among Women and Older Adults
New preliminary research shows that extreme heat significantly increases out-of-hospital cardiac arrest ICU admissions, straining hospital resources d...

Former Academic and Biotech Scientist Releases Free Go/No-Go Checklist to Curb Costly Biotherapeutic Failures
Catherine Cifuentes-Rojas, a director at Ginkgo Bioworks, has published a free five-question checklist to help early-stage biotherapeutics teams make ...

Quantum BioPharma Partners with Thermo Fisher for Phase 2 Lucid-MS Trial in Progressive MS
Quantum BioPharma's agreement with Thermo Fisher's clinical research business marks a key step toward launching a Phase 2 trial for Lucid-MS, a novel ...

Annovis Bio CEO to Present at Two November Biotechnology Conferences
Annovis Bio's CEO will present at two November industry conferences, providing a platform to highlight the company's clinical programs and upcoming mi...

NanoViricides Advances Oral Ebola Treatment Trial as DRC Outbreak Grows
NanoViricides reports progress in its Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo, the only oral drug candidate in clinical evaluation...

Mutated Flu Virus Drives Early West Coast Outbreak, Prompting Urgent Vaccination Calls
A mutated flu strain spreading early on the West Coast has prompted urgent vaccination calls and highlighted the role of decentralized testing tools f...

Tonix's TONMYA Shows Promise as First-Line Non-Opioid Fibromyalgia Treatment in Phase 3 Trials
Tonix Pharmaceuticals' TONMYA demonstrated statistically significant improvements in pain and physical function in two Phase 3 trials, positioning it ...

Tonix Pharmaceuticals Sets Nov. 9 Date for Q3 2026 Financial Results, Spotlight on TONMYA Launch
Tonix Pharmaceuticals will report third-quarter 2026 financial results on Nov. 9, an event that will give investors the first detailed look at how its...

Annovis Bio to Present Buntanetap Data at CTAD, Signaling Progress Toward 2027 Pivotal Readout
Annovis Bio's three presentations at the 2026 CTAD conference will showcase buntanetap's mechanism, Phase 3 trial design, and AI-driven blood-brain ba...

NeuroThera Labs Clears Key Manufacturing Hurdle for FDA-Approved Tourette Syndrome Trial
NeuroThera Labs has completed manufacturing and obtained European batch release certification for its Tourette Syndrome drug candidate SCI-110, enabli...

BioVersys BV100 Data Show Strong Lung Penetration and Manageable Drug Interactions, Bolstering Phase 3 Case
BioVersys announced peer-reviewed publications showing its antibiotic BV100 achieves high lung concentrations and has a milder drug-interaction profil...

Quantum BioPharma's Unbuzzd Draws National Spotlight, But Clinical Caveats Temper Enthusiasm
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article, yet the piece underscores that s...

NanoViricides' Pediatric Safety Data for NV-387 Could Unlock Trials for Ebola, Mpox, and Measles
NanoViricides reported positive juvenile animal safety results for its broad-spectrum antiviral NV-387, potentially enabling pediatric clinical trials...

Quantum BioPharma's Unbuzzd Draws National Spotlight, But Clinical Caveats Temper Enthusiasm
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness feature, yet the article's emphasis on sm...

Tonix's TONMYA Fibromyalgia Data to Debut at 2026 World Congress on Pain
Tonix Pharmaceuticals will present new data on its recently approved fibromyalgia drug TONMYA at the 2026 IASP World Congress on Pain, underscoring th...

Measles Infections Leave Lasting Immune Damage, Experts Warn
New evidence shows measles triggers lasting vulnerabilities in the immune system, making survivors susceptible to other infections, and highlights the...

Tonix Pharmaceuticals to Present TNX-801 Vaccine Platform at World Vaccine Congress Europe
Tonix Pharmaceuticals will present its TNX-801 vaccine platform at the World Vaccine Congress Europe, highlighting its potential to address mpox and o...

OrthodontiCell Secures Capital to Advance Bioelectric Orthodontic Technology Toward U.S. Pivotal Study
OrthodontiCell has secured funding to complete testing for a planned U.S. Phase II pivotal study of its bioelectric technology that aims to accelerate...

hyperCORE International Elects New Officers to Drive Growth for Site Networks and CROs
hyperCORE International has elected new officers to lead its strategic scaling platform, aiming to accelerate growth for independent site networks and...

FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 Trial, Advancing a Non-Immunosuppressive Approach to Multiple Sclerosis
Quantum BioPharma has received FDA clearance to begin Phase 2 testing of Lucid-MS, a first-in-class multiple sclerosis candidate that aims to protect ...

American Heart Association Names Five Finalists for 2026 Health Tech Competition
The American Heart Association has selected five finalists for its 2026 Health Tech Competition, highlighting innovations that could accelerate adopti...

NanoViricides Advances NV-387 Oral Gummies into Phase IIA Ebola Trial, Targeting a Deadly Virus with a Broad-Spectrum Platform
NanoViricides' Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo virus marks a critical step in developing an oral, broad-spectrum antiviral...

